期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Post-Surgical Recurrence of Hepatocellular Carcinoma 被引量:1
1
作者 CHENG Hongyan Department of Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China 《The Chinese-German Journal of Clinical Oncology》 CAS 2002年第1期30-31,共2页
Objective To analyze post-surgical recurrence of hepatocellular carcinoma (HHC) according to pathologic findings, primary tumor and angiographic features of the recurrent tumor.Methods In this series, 100 cases of rec... Objective To analyze post-surgical recurrence of hepatocellular carcinoma (HHC) according to pathologic findings, primary tumor and angiographic features of the recurrent tumor.Methods In this series, 100 cases of recurrent HCC were analyzed in following aspects: ( 1) size, tumor nodular numbers, gross and histologic findings of the primary tumor; (2) post-surgical recurrent time; (3) size, tumor nodular numbers, blood supply, staining property, and accumulation of lipiodol oil in the recurrent tumor. Following angiography, arterial chemoembolization was performed. Results In the primary tumor, single nodules were seen in 80 cases, multiple nodules in 16 cases and multiple fused nodules in 4 cases. All tumors were classified as: trabecular type, 65 cases; compact type, 12; sclerotic type, 2 cases; mixed type, 15 cases and cholangiocarcinoma type, 6 cases. 38 cases had incomplete or no capsule. Satellite tumor nodules were grossly identified during operation in 33 cases, but were proven microscopically in 66 cases. Tumor thrombi of portal vein was noted in 18 cases during oeration, but 85 cases in histopathological sections. The recurrent tumors were diagnosed post surgically within 6 months in 67 cases, 6-12 months in 15 cases and after 12 months in 18 cases respectively. On angiography, 67 % recurrent tumors was rich in blood supply and with abundant accumulation of lipiodol after embolization.Conclusion The post-surgical recurrence rate of the HCC patients with massive size, incomplete or no capsule, satellite tumor nodules and portal vein tumor thrombus was high. The patients shoud receive angiography in 1 ?2 months after surgery in order to detect early recurrence and, if confirmed, the patients may be treated by transcatheter arterial chemoembolization 展开更多
关键词 hepatocellular carcinoma RECURRENCE
下载PDF
CircuLite公司开发出世界上最小的一次性植入可长期使用的微型血液循环支持系统SYNERGY~
2
作者 范鸣 《药学进展》 CAS 2013年第4期181-181,共1页
德国CircuLite公司于2013年3月5日宣布,其研制的血液循环支持系统SYNERGY已有条件获美国FDA的临床试验用医疗器材豁免(IDE)认证,并计划开始在美国开展一项临床试验评价该产品用于其他疗法无效的无需卧床的慢性心衰患者[国际机械辅... 德国CircuLite公司于2013年3月5日宣布,其研制的血液循环支持系统SYNERGY已有条件获美国FDA的临床试验用医疗器材豁免(IDE)认证,并计划开始在美国开展一项临床试验评价该产品用于其他疗法无效的无需卧床的慢性心衰患者[国际机械辅助循环支持研究协会制定的心衰等级标准(INTERMACS)为4级及以上或纽约心脏病学会规定的心功能分级(NYHA)为III/IV@]长期支持治疗的安全性和功效, 展开更多
关键词 SYNERGY 微型血液循环支持 微创手术 心衰
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部